Table 2. Efficacy of PKC412 for the treatment of 4ZF- or 10ZF-induced myeloproliferative disorder.

	Placebo	PKC412
4ZF BMT mice
Spleen weight/median, mg	389-568.4/460.1	27-204.6/93.4
WBC count/median, 106/ml	45.25-265/136	0.96-11.07/3
n	9	8
10ZF BMT mice
Spleen weight/median, mg	361-822/522.1	28-122/83.5
n	11	10
WBC count/median, 106/ml	91.02-227.4/122	0.87-3.31/2.34
n	11	7

n, number of animals.